Pharmacogenomics of Antiplatelet Response
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 45 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| End Date: | May 2015 |
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene
expression in persons at high-risk of developing heart attacks due to family history of
early-onset coronary artery disease
expression in persons at high-risk of developing heart attacks due to family history of
early-onset coronary artery disease
In this clinical trials we will select individuals from GeneSTAR cohort based o their
platelet function. Equal number of individuals will be selected from each race and gender
and from low or high platelet aggregation. We will have baseline platelet functions
performed and baseline platelet gene expression examined. Participants will be given 2-week
supply of aspirin(81 mg/daily) and will be examined at the end of 2-weeks with platelet
aggregation studies and a repeat platelet gene-expression (using RNA-seq). The ultimate goal
is to examine platelet gene expression differences due to aspirin and across different
gender, race, platelet-aggregation groups.
platelet function. Equal number of individuals will be selected from each race and gender
and from low or high platelet aggregation. We will have baseline platelet functions
performed and baseline platelet gene expression examined. Participants will be given 2-week
supply of aspirin(81 mg/daily) and will be examined at the end of 2-weeks with platelet
aggregation studies and a repeat platelet gene-expression (using RNA-seq). The ultimate goal
is to examine platelet gene expression differences due to aspirin and across different
gender, race, platelet-aggregation groups.
Inclusion Criteria:
- 45-75 years
- GeneSTAR participant
- No personal History of Coronary Artery Disease
- Women who are post-menopausal
- Women who are using a reliable method of contraception, such as history of tubal
ligation, IUD or taking OCP
Exclusion Criteria:
- Taking aspirin prescribed by physician
- weight < 60 kg
- History of recent or current bleeding
- allergy to aspirin or history of adverse events to aspirin
- serious comorbid conditions (such as AIDS, active cancer)
- high blood pressure (>160/95)
- History of gastrointestinal ulcer/bleeding
- Mental incompetence to make decision to participate.
We found this trial at
1
site
Click here to add this to my saved trials
